Last year we were faced with decisions when a major problem arose in one of the companies which manufactures the recombinant or synthetic blood products. We were suddenly faced with a shortage of those products, which meant we had to contemplate moving back to blood derived products. Where was the source for those blood derived products? The United States. That is because it is the one country that does not have BSE or CJD.